在阿尔法-2-抗等离子素缺乏患者中增强的血栓和等离子素生成概况:来自荷兰罕见出血障碍研究的数据
Bauke Haisma1,2, Sanna R Rijpma2,3, Marjon H Cnossen4
1Department of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands.
Research and practice in thrombosis and haemostasis
|December 4, 2024
概括
阿尔法2-抗等离子素 (A2AP) 缺乏导致纤维素分解和出血的增加. 这项研究发现,A2AP缺乏症患者表现出高血和血栓生成,与出血严重程度相关.
科学领域:
- 血液学 血液学 血液学
- 血液静止和血栓形成研究
- 罕见的出血疾病 罕见的出血疾病
背景情况:
- 阿尔法2-抗等离子素 (A2AP) 缺乏症是一种罕见的疾病,导致过度纤维解和出血.
- 全球血静定测试可以阐明A2AP缺乏症中的凝血和纤维素分解变化.
研究的目的:
- 为了研究A2AP缺乏患者的血栓激素和等离子体生成概况.
- 为了将这些概况与A2AP活动水平和出血表型相关联.
主要方法:
- 在23名A2AP缺乏症患者和37名健康对照中,使用尼米根血液静止试验来测量血栓和等离子体生成.
- 分析的关键参数包括血/等离子素峰值高度,血/等离子素潜力和纤维素溶解时间.
- 数据与A2AP活动和ISTH出血评估工具得分相关联.
主要成果:
- 缺乏A2AP的患者表现出显著增加的等离子体生成 (更短的溶解时间,更高的峰值高度/潜力/速度).
- 在A2AP缺乏患者中也观察到高血栓生成 (更高的峰值高度和潜力).
- 增强的等离子体生成与较低的A2AP活性和更严重的出血表型有显著的相关性.
结论:
- A2AP缺乏与增强的等离子体生成有关,直接与A2AP活性和出血严重程度有关.
- 该研究还确定了A2AP缺乏个体中血栓生成概况的增加.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
616
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
616
Clot Retraction and Fibrinolysis
4.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
4.0K
Disorders of Hemostasis
707
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
707
Formation of the Platelet Plug
4.4K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
4.4K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K


